Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases

被引:16
|
作者
Ramesha, K. N. [1 ]
Kuruvilla, Abraham [1 ]
Sarma, P. S. [2 ]
Radhakrishnan, V. V. [3 ]
机构
[1] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Neurol, Trivandrum 695011, Kerala, India
[2] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Biostat, Trivandrum 695011, Kerala, India
[3] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Neuropathol, Trivandrum 695011, Kerala, India
关键词
Final outcome; myositis; prognosis; survival rate;
D O I
10.4103/0972-2327.74190
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To study the electroclinical and histopathologic profile of idiopathic inflammatory myositis (IIM) with reference to prognosis and survival rate. Materials and Methods: Diagnosis of IIM was based on the Bohan and Peter criteria. Patients who improved and those whose condition worsened or who expired due to IIM per se at last follow-up were classified to have favorable and poor outcomes, respectively. Fishers exact test was used for univariate analysis of prognostic factors. Results: The study cohort consisted of consecutive 68 patients with IIM. The mean age at diagnosis was 36.5 years and females constituted 71%. Of these patients, 62% had definite IIM, 49% had polymyositis, 20% had dermatomyositis, and 29% had overlap syndrome. The mean follow-up period was 5.4 years. Prednisolone alone was used in 55 (80%), and azathioprine (1-3 mg/kg/day) alone in 12 (17.6%) as the initial treatment. Relapse of IIM with drug withdrawal was seen in 15 patients (22%); 70% had favorable outcome and 16% had expired. The treatment delay of %6 months (P = 0.001), absence of cardiac or lung involvement (P < 0.001), and positive biopsy (P = 0.033) were predictive of a favorable prognosis in the univariate analysis. In multivariate analysis, only the duration of illness of %6 months (P = 0.008) and the absence of cardiac or lung involvement (P = 0.001) predicted the favorable outcome at last follow-up. Cumulative survival rate was 95% at 1 year, 86% at the 5th year, and 80% at the 10th year. Conclusions: Approximately, two-thirds of the patients showed good electroclinical and histopathologic correlations and an equal number improved with treatment. The treatment delay (>= 6 months), presence of cardiac or pulmonary involvements, and negative muscle biopsy are bad prognostic factors.
引用
收藏
页码:250 / 256
页数:7
相关论文
共 50 条
  • [31] Clinical and serological characteristics of myositis: Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies
    Hengstman, GJD
    van Venrooij, WJ
    Egberts, WTMV
    van Engelen, BGM
    NEUROLOGY, 2000, 54 (07) : A240 - A240
  • [32] SINGLE CENTER EXPERIENCE OF CLINICAL PROFILE OF INFLAMMATORY MYOSITIS FROM INDIA
    Kulkarni, N.
    Venugopalan, A.
    Saluja, M.
    Chopra, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1586 - 1586
  • [33] Clinical profile and outcome of idiopathic restrictive cardiomyopathy -: Response
    Ammash, NM
    Tajik, AJ
    Seward, JB
    Edwards, WD
    Bailey, KR
    CIRCULATION, 2001, 103 (14) : E83 - E83
  • [34] The prevalence and clinical associations of myositis specific and associated autoantibodies in idiopathic inflammatory myopathy
    Gunawardena, Harsha
    Betteridge, Zoe E.
    McHugh, Neil J.
    RHEUMATOLOGY, 2008, 47 : II84 - II85
  • [35] Low serum complements in idiopathic inflammatory myositis: clinical features and impact on the prognosis
    Nomura, Shun
    Shimojima, Yasuhiro
    Kishida, Dai
    Ichikawa, Takanori
    Matsushima, Akira
    Sekijima, Yoshiki
    IMMUNOLOGICAL MEDICINE, 2024,
  • [36] Clinical profile and outcome of dengue fever cases
    Ratageri V.H.
    Shepur T.A.
    Wari P.K.
    Chavan S.C.
    Mujahid I.B.
    Yergolkar P.N.
    The Indian Journal of Pediatrics, 2005, 72 (8) : 705 - 706
  • [37] "ARE MYOSITIS ANTIBODIES SPECIFIC FOR IDIOPATHIC INFLAMMATORY MYOPATHY DIAGNOSIS?" CLINICAL CORRELATION OF A COHORT OF PATIENTS POSITIVE FOR MYOSITIS ANTIBODIES
    Loarce-Martos, J.
    Rita, C.
    Ballester Gonzalez, R.
    Calvo Sanz, L.
    Garrote Corral, S.
    Garcia-Soidan, A.
    Garcia-Hoz, C.
    Iturrieta-Zuazo, I.
    Bachiller-Corral, J.
    Roy, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 705 - 705
  • [38] TREATMENT OF INFLAMMATORY MYOSITIS IN CLINICAL PRACTICE: ANALYSIS OF THE REGISTRY OF INFLAMMATORY MYOSITIS FROM THE MADRID COMMUNITY (REMICAM)
    Joven-Ibanez, Beatriz
    Nuno, Laura
    Lopez-Longo, Francisco J.
    Martinez-Barrio, Julia
    Larena, Carmen
    Maldonado, Valentina
    Barbadillo, Carmen
    Garcia de la Pena, Paloma
    Llorente, Irene
    Tomero Muriel, Eva
    Perez Gomez, Ana
    Moruno, Henry
    Cobo-Ibanez, Tatiana
    Almodovar, Raquel
    Lojo, Leticia
    Jesus Garcia de Yebenes, Maria
    Carreira, Patricia
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1559 - 1560
  • [39] Clinical analysis of 26 cases of myositis ossificans circumscripta
    李军
    朱丽萍
    胡永吉
    刘淼
    Chinese Journal of Traumatology, 2000, (02)
  • [40] Clinical analysis of 26 cases of myositis ossificans circumscripta
    李军
    朱丽萍
    胡永吉
    刘淼
    中华创伤杂志(英文版), 2000, (02) : 60 - 61